Rexahn Pharmaceuticals, Inc. (NYSE:RNN) saw a large increase in short interest in the month of September. As of September 30th, there was short interest totalling 1,087,401 shares, an increase of 44.4% from the September 15th total of 752,788 shares. Currently, 0.5% of the shares of the stock are sold short. Based on an average daily volume of 1,116,332 shares, the short-interest ratio is presently 1.0 days.
Several equities research analysts have recently weighed in on RNN shares. Zacks Investment Research upgraded Rexahn Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, June 21st. FBR & Co reiterated an “outperform” rating and issued a $3.00 price objective on shares of Rexahn Pharmaceuticals in a research note on Wednesday, October 5th.
A hedge fund recently raised its stake in Rexahn Pharmaceuticals stock. Vanguard Group Inc. boosted its stake in shares of Rexahn Pharmaceuticals, Inc. (NYSE:RNN) by 1.0% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,904,097 shares of the company’s stock after buying an additional 49,761 shares during the period. Vanguard Group Inc. owned 2.30% of Rexahn Pharmaceuticals worth $1,232,000 at the end of the most recent quarter.
Shares of Rexahn Pharmaceuticals (NYSE:RNN) opened at 0.1817 on Friday. Rexahn Pharmaceuticals has a 1-year low of $0.18 and a 1-year high of $0.52. The stock has a 50 day moving average price of $0.23 and a 200 day moving average price of $0.27. The company’s market capitalization is $38.76 million.
Rexahn Pharmaceuticals (NYSE:RNN) last announced its quarterly earnings data on Monday, August 8th. The company reported ($0.01) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.02) by $0.01. Analysts forecast that Rexahn Pharmaceuticals will post ($0.07) earnings per share for the current year.
About Rexahn Pharmaceuticals
Rexahn Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of treatments for cancer. The Company’s clinical-stage drug candidates in active development include Archexin, RX-3117 and Supinoxin (RX-5902). Archexin is a potent inhibitor of the protein kinase Akt-1, which focuses on cancer cell proliferation, survival, angiogenesis, metastasis and drug resistance.
Receive News & Ratings for Rexahn Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rexahn Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.